Patents Represented by Attorney Michael J. Brignati
-
Patent number: 8318904Abstract: The present invention is directed to liquid, aqueous pharmaceutical compositions stabilized against chemical and/or physical degradation containing Factor VII polypeptides, and methods for preparing and using such compositions, as well as vials containing such compositions, and the use of such compositions in the treatment of a Factor VII-responsive syndrome. The main embodiment is represented by a liquid, aqueous pharmaceutical composition comprising at least 0.01 mg/mL of a Factor VII polypeptide (i); a buffering agent (ii) suitable for keeping pH in the range of from about 4.0 to about 9.0; and at least one stabilizing agent (iii) comprising a —C(?N—Z1—R1)—NH—Z2—R2 motif, e.g. benzamidine compounds and guanidine compounds such as arginine.Type: GrantFiled: September 16, 2011Date of Patent: November 27, 2012Assignee: Novo Nordisk Health Care AGInventors: Michael Bech Jensen, Anders Klarskov Petersen, Andrew Neil Bowler
-
Patent number: 8299029Abstract: The invention relates to chemically as well as physically stable compositions comprising Factor VII or a Factor VII-related polypeptide such that these compositions can be stored, handled and used at room temperature.Type: GrantFiled: September 25, 2006Date of Patent: October 30, 2012Assignee: Novo Nordisk Health Care AGInventors: Michael Bech Jensen, Birthe Lykkegaard Hansen, Troels Kornfelt
-
Patent number: 8287861Abstract: Anti-human IL20 monoclonal antibodies that can reduce IL20 mediated activation of both IL20R1/IL20R2 and IL22R1/IL20R2 receptor complexes in one or more species, including humans, are described, as well as antigen-binding molecules such as, e.g., antigen-binding antibody fragments, antibody derivatives, and multi-specific molecules designed or derived from such antibodies, and methods or producing such antibodies or other antigen-binding molecules. Such antibodies or other antigen-binding molecules can be used for treating various diseases and disorders, including autoimmune or inflammatory diseases or disorders.Type: GrantFiled: June 30, 2009Date of Patent: October 16, 2012Assignee: Novo Nordisk A/SInventors: Jesper Pass, Søren Østergaard, Jes Thorn Clausen
-
Patent number: 8153395Abstract: The invention is related to a method for making an activated carboxypeptidase in a fungi cell comprising introducing a DNA sequence encoding a proform of the carboxypeptidase wherein a Kex2 site has been introduced in the prosequence of the carboxypeptidase, culturing the fungi cell under conditions suitable for expression of the procarboxypeptidase and cleaving off the prosequence within the cell to liberate the free active form of the carboxypeptidase. The invention is also related to methods for making mature human insulin and human insulin analogues by use of the activated carboxypeptidase enzyme.Type: GrantFiled: November 21, 2007Date of Patent: April 10, 2012Assignee: Novo Nordisk A/SInventor: Per Nørgaard
-
Patent number: 8133975Abstract: The present invention relates to novel coagulation Factor VII polypeptides, polynucleotide constructs encoding such polypeptides, as well as vectors and host cells comprising and expressing the polynucleotide, pharmaceutical compositions, uses and methods of treatment.Type: GrantFiled: April 19, 2010Date of Patent: March 13, 2012Assignee: Novo Nordisk Health Care A/GInventor: Henrik Østergaard
-
Patent number: 8129146Abstract: Novel insulin precursors and insulin precursor analogs comprising a connecting peptide (mini C-peptide) of preferably up to 15 amino acid residues and comprising at least one Gly are provided. The precursors can be converted into human insulin or a human insulin analog. The precursors will typically have a distance between B27 (atom CG2) and A1 (atom CA) of less than 5 ?.Type: GrantFiled: April 17, 2008Date of Patent: March 6, 2012Assignee: Novo Nordisk A/SInventors: Thomas Borglum Kjeldsen, Svend Ludvigsen
-
Patent number: 8114833Abstract: The present invention relates to pharmaceutical formulations comprising a peptide and propylene glycol, to methods of preparing such formulations, and to uses of such formulations in the treatment of diseases and conditions for which use of the peptide contained in such formulations is indicated. The present invention further relates to methods for reducing the clogging of injection devices by a peptide formulation and for reducing deposits on production equipment during production of a peptide formulation.Type: GrantFiled: May 17, 2006Date of Patent: February 14, 2012Assignee: Novo Nordisk A/SInventors: Tina Bjeldskov Pedersen, Claude Bonde, Dorthe Kot Engelund
-
Patent number: 8097584Abstract: The present invention relates to a pharmaceutical formulation comprising insulin, an insulin analogue or an insulin derivate and ethylenediamine or salts thereof and an antimicrobial preservative agent.Type: GrantFiled: May 22, 2006Date of Patent: January 17, 2012Assignee: Novo Nordisk A/SInventor: Christian Poulsen
-
Patent number: 8084587Abstract: The present invention relates to a process for the purification of a protease.Type: GrantFiled: January 26, 2010Date of Patent: December 27, 2011Assignee: Novo Nordisk Health Care AGInventors: Janus Krarup, Egon Persson
-
Patent number: 8067554Abstract: The present invention relates to an ion exchange chromatography process for purifying GLP-1 or an analog or a derivative thereof from a mixture containing said GLP-1 and related impurities, and to an industrial method including such ion exchange chromatography process.Type: GrantFiled: May 29, 2007Date of Patent: November 29, 2011Assignee: Novo Nordisk A/SInventor: Arne Staby
-
Patent number: 8053410Abstract: The invention concerns a preparation comprising a plurality of Factor VII polypeptides or Factor VII-related polypeptides, wherein the polypeptides comprise asparagine-linked and/or serine-linked oligosaccharide chains, and wherein at least one oligosaccharide group is covalently attached to at least one polymeric group.Type: GrantFiled: February 13, 2009Date of Patent: November 8, 2011Assignee: Novo Nordisk Health Care A/GInventors: Niels Kristian Klausen, Soren Bjorn, Carsten Behrens, Patrick William Garibay
-
Patent number: 8026214Abstract: The present invention is directed to liquid, aqueous pharmaceutical compositions stabilised against chemical and/or physical degradation containing Factor VII polypeptides, and methods for preparing and using such compositions, as well as vials containing such compositions, and the use of such compositions in the treatment of a Factor VII-responsive syndrome. The main embodiment is represented by a liquid, aqueous pharmaceutical composition comprising at least 0.01 mg/mL of a Factor VII polypeptide (i); a buffering agent (ii) suitable for keeping pH in the range of from about 4.0 to about 9.0; and at least one stabilising agent (iii) comprising a —C(?N—Z1—R1)—NH—Z2—R2 motif, e.g. benzamidine compounds and guanidine compounds such as arginine.Type: GrantFiled: November 12, 2009Date of Patent: September 27, 2011Assignee: Novo Nordisk Health Care AGInventors: Michael Bech Jensen, Anders Klarskov Petersen, Andrew Neil Bowler
-
Patent number: 8022031Abstract: A liquid aqueous composition comprising (i) a factor VII polypeptide, (ii) an agent suitable for keeping pH in the range of from about 4.0 to about 8.0; (iii) an agent selected from the list of: a calcium salt, a magnesium salt, or a mixture thereof; wherein the concentration of (iii) is at least 15 mM.Type: GrantFiled: June 24, 2003Date of Patent: September 20, 2011Assignee: Novo Nordisk Health Care A/GInventors: Birthe Lykkegaard Hansen, Michael Bech Jensen, Troels Kornfelt
-
Patent number: 8003605Abstract: A method for minimizing weight gain, preventing weight gain or inducing weight loss in a mammal, said method involving a treatment regimen which comprises administration of an insulin derivative having a substituent containing from 6 to 40 carbon atoms attached to one of its amino acid residues.Type: GrantFiled: March 12, 2003Date of Patent: August 23, 2011Assignee: Novo Nordisk A/SInventors: Thomas Bayer, Signe Rikke Permild, legal representative, Birgitte Sogaard, Mads Axelsen